摘要
目的观察微小RNA(miRNA,miR)-185在骨肉瘤患者中的表达,探讨其在骨肉瘤诊断及预后中的价值。方法采用实时定量反转录聚合酶链反应(RT-qPCR)技术检测54对骨肉瘤患者和健康对照者(性别和年龄匹配)的miR-185表达。根据miR-185的中位数(2.381),将所有患者分为两组:高miR-185表达组(21)和低miR-185表达组(33)。然后分析miR-185表达与患者临床病理因素的相关性。血清样本在郑州大学第一附属医院2012年1月1日至2014年12月份从接受手术但未接受化学疗法或放射疗法的患者中收集,并分析miR-185表达与骨肉瘤患者的临床病理特征和总体生存率的关系。使用Manne WhitneyU检验比较骨肉瘤患者和正常对照组血清miR-185水平的差异。对数秩检验和Kaplan-Meier方法评估骨肉瘤患者的总体生存率。采用Cox回归和多因素分析评估预后价值。结果与正常对照组比较,骨肉瘤患者血清中的miR-185表达显著降低(U=373.000,P<0.05),差异有统计学意义。miR-185的低表达与较大的肿瘤体积(直径<5 cm比直径≥5 cm的miR-185:3.100±0.359比1.806±0.226,P<0.01),较高的TNM分期(一、二期比三、四期的miR-185:2.986±1.562比1.566±1.305,P<0.01)和远处转移(未转移比转移的miR-185:3.014±1.660比1.590±1.148,P<0.01)密切相关,差异有统计学意义。Kaplan-Meier曲线生存分析和对数秩检验显示,miR-185的低表达与骨肉瘤患者的总生存率降低有关。此外,多变量分析表明,miR-185表达降低是骨肉瘤患者总体生存的独立预后生物标志物(P<0.01),差异有统计学意义。结论血清miR-185可作为一种肿瘤抑制因子,有助于骨肉瘤患者的诊断、预后。
Objective To observe the expression level of microRNA(miRNA,miR)-185 in osteosarcoma patients and evaluate the diagnostic and prognostic value of the miRNA.Methods The expression level of miR-185 was detected by quantitative real-time reverse transcriptase polymerase chain reaction(RT-qPCR)analysis using 54 pairs of osteosarcoma patients and matched healthy controls.According to the median of miR-185(2.381),all patients were divided into two groups:high miR-185 expression group(21)and low miR-185 expression group(33).Then,the associations of miR-185 expression with clinicopathologic features of osteosarcoma patients were determined.Serum samples were collected from patients who underwent surgery but did not receive chemotherapy or radiation therapy between January 1,2012 and December 31,2014,and analyzed the relationship between miR-185 expression and the clinical pathological characteristics and overall survival rate of osteosarcoma patients.The Manne Whitney U test was used to compare the difference in serum miR-185 levels between the osteosarcoma patient group and the normal control group.Log rank test and Kaplan-Meier method were used to evaluate the overall survival rate of osteosarcoma patients.Cox regression and multi-factor analysis were used to evaluate the prognostic value.Results Our findings showed that the miR-185 expression was significantly decreased in serum of osteosarcoma patients compared to normal controls(U=373.000,P<0.01).Moreover,down-regulation of miR-185 more frequently occurred in osteosarcoma patients with large tumor size(diameter<5 cm vs.diameter≥5 cm:3.100±0.359 vs.1.806±0.226,P<0.01),advanced TNM stage(stageⅠandⅡvs.stageⅢandⅣ:2.986±1.562 vs.1.566±1.305,P<0.01)and distant metastasis(premetastaticvs.metastasis:3.014±1.660 vs.1.590±1.148,P<0.01).Furthermore,Kaplan-Meier survival analysis and log-rank test revealed that low expression of miR-185 was associated with the reduced overall survival of patients with osteosarcoma.In addition,the multivariate analysis suggested
作者
孙建广
皮国富
李峰
黄世磊
罗成汉
韩钰
Sun Jianguang;Pi Guofu;Li Feng;Huang Shilei;Luo Chenghan;Han Yu(Department of Orthopaedics,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2020年第4期761-763,共3页
Chinese Journal of Experimental Surgery
